Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension

Authors: Ananda T Dias, Bianca P Rodrigues, Marcella L Porto, Agata L Gava, Camille M Balarini, Flavia P S Freitas, Zaira Palomino, Dulce E Casarini, Bianca P Campagnaro, Thiago M C Pereira, Silvana S Meyrelles, Elisardo C Vasquez

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Oxidative stress and DNA damage have been implicated in the pathogenesis of renovascular hypertension induced by renal artery stenosis in the two-kidney, one-clip (2K1C) Goldblatt model. Considering our previous report indicating that the chronic blockade of phosphodiesterase 5 with sildenafil (Viagra®) has marked beneficial effects on oxidative stress and DNA damage, we tested the hypothesis that sildenafil could also protect the stenotic kidneys of 2K1C hypertensive mice against oxidative stress and genotoxicity.

Methods

The experiments were performed with C57BL6 mice subjected to renovascular hypertension by left renal artery clipping. Two weeks after clipping, the mice were treated with sildenafil (40 mg/kg/day for 2 weeks, 2K1C-sildenafil group) or the vehicle (2K1C). These mice were compared with control mice not subjected to renal artery clipping (Sham). After hemodynamic measurements, the stenotic kidneys were assessed using flow cytometry to evaluate cell viability and the comet assay to evaluate DNA damage. Measurements of intracellular superoxide anions and hydrogen peroxide levels as well as nitric oxide bioavailability were also obtained.

Results

Sildenafil treatment significantly reduced mean arterial pressure (15%), heart rate (8%), intrarenal angiotensin II (50%) and renal atrophy (36%). In addition, it caused a remarkable decrease of reactive oxygen species production. On the other hand, sildenafil increased nitric oxide levels relative to those in the nontreated 2K1C mice. Sildenafil treatment also significantly reduced the high level of kidney DNA damage that is a characteristic of renovascular hypertensive mice.

Conclusions

Our data reveal that sildenafil has a protective effect on the stenotic kidneys of 2K1C mice, suggesting a new use of phosphodiesterase 5 inhibitors for protection against the DNA damage observed in the hypoperfused kidneys of individuals with renovascular hypertension. Further translational research is necessary to delineate the mechanisms involved in the prevention of renal stenosis in the clinical setting.
Appendix
Available only for authorised users
Literature
1.
Pereira TM, Balarini CM, Silva IV, Cabral AM, Vasquez EC, Meyrelles SS: Endogenous angiotensin II modulates nNOS expression in renovascular hypertension. Braz J Med Biol Res. 2009, 42 (7): 685-691. 10.1590/S0100-879X2009000700014.CrossRefPubMed
2.
Stegbauer J, Friedrich S, Potthoff SA, Broekmans K, Cortese-Krott MM, Quack I, Rump LC, Koesling D, Mergia E: Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension. PLoS One. 2013, 8 (11): e80674-10.1371/journal.pone.0080674.PubMedCentralCrossRefPubMed
3.
Nogueira BV, Palomino Z, Porto ML, Balarini CM, Pereira TM, Baldo MP, Casarini DE, Meyrelles SS, Vasquez EC: Granulocyte colony stimulating factor prevents kidney infarction and attenuates renovascular hypertension. Cell Physiol Biochem. 2012, 29 (1–2): 143-152.CrossRefPubMed
4.
Kelsen S, He X, Chade AR: Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney. Am J Physiol Renal Physiol. 2012, 303 (4): F576-F583. 10.1152/ajprenal.00154.2012.PubMedCentralCrossRefPubMed
5.
Welch WJ, Mendonca M, Aslam S, Wilcox CS: Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K1C kidney. Hypertension. 2003, 41 (3 Pt 2): 692-696.CrossRefPubMed
6.
Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO: Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol. 2004, 15 (4): 958-966. 10.1097/01.ASN.0000117774.83396.E9.CrossRefPubMed
7.
Chatterjee PK: Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol. 2007, 376 (1–2): 1-43.CrossRefPubMed
8.
Kalyanaraman B: Teaching the basics of redox biology to medical and graduate students: Oxidants, antioxidants and disease mechanisms. Redox Biol. 2013, 1 (1): 244-257. 10.1016/j.redox.2013.01.014.PubMedCentralCrossRefPubMed
9.
Cabral AM, Vasquez EC: Time course of cardiac sympathetic and vagal tone changes in renovascular hypertensive rats. Am J Hypertens. 1991, 4 (10 Pt 1): 815-819. 10.1093/ajh/4.10.815.CrossRefPubMed
10.
Moyses MR, Cabral AM, Marçal D, Vasquez EC: Sigmoidal curve-fitting of baroreceptor sensitivity in renovascular 2K1C hypertensive rats. Braz J Med Biol Res. 1994, 27 (6): 1419-1424.PubMed
11.
Vasquez EC, Meyrelles SS, Mauad H, Cabral AM: Neural reflex regulation of arterial pressure in pathophysiological conditions: interplay among the baroreflex, the cardiopulmonary reflexes and the chemoreflex. Braz J Med Biol Res. 1997, 30 (4): 521-532. 10.1590/S0100-879X1997000400014.CrossRefPubMed
12.
Abreu GR, Futuro-Neto HA, Cabral AM, Vasquez EC: L-arginine restores the effect of ouabain on baroreceptor activity and prevents hypertension. Hypertension. 1999, 34 (4 Pt 2): 729-732.CrossRefPubMed
13.
Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC: Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension. 2005, 46: 932-936. 10.1161/01.HYP.0000182154.61862.52.CrossRefPubMed
14.
Nogueira BV, Peotta VA, Meyrelles SS, Vasquez EC: Evaluation of aortic remodeling in apolipoprotein E-deficient mice and renovascular hypertensive mice. Arch Med Res. 2007, 38 (8): 816-821. 10.1016/j.arcmed.2007.06.005.CrossRefPubMed
15.
Peotta VA, Gava AL, Vasquez EC, Meyrelles SS: Evaluation of baroreflex control of heart rate in renovascular hypertensive mice. Can J Physiol Pharmacol. 2007, 85 (8): 761-766. 10.1139/Y07-067.CrossRefPubMed
16.
Gava AL, Peotta VA, Cabral AM, Vasquez EC, Meyrelles SS: Overexpression of eNOS prevents the development of renovascular hypertension in mice. Can J Physiol Pharmacol. 2008, 86 (7): 458-464. 10.1139/Y08-044.CrossRefPubMed
17.
Campagnaro BP, Gava AL, Meyrelles SS, Vasquez EC: Cardiac-autonomic imbalance and baroreflex dysfunction in the renovascular angiotensin-dependent hypertensive mouse. Int J Hypertens. 2012, 2012: 968123-PubMedCentralCrossRefPubMed
18.
Campagnaro BP, Tonini CL, Nogueira BV, Casarini DE, Vasquez EC, Meyrelles SS: DNA damage and augmented oxidative stress in bone marrow mononuclear cells from Angiotensin-dependent hypertensive mice. Int J Hyoertens. 2013, 2013: 305202-
19.
Campagnaro BP, Tonini CL, Doche LM, Nogueira BV, Vasquez EC, Meyrelles SS: Renovascular hypertension leads to DNA damage and apoptosis in bone marrow cells. DNA Cell Biol. 2013, 32 (8): 458-466. 10.1089/dna.2013.2065.PubMedCentralCrossRefPubMed
20.
Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, Takamatsu I, Tatematsu S, Ozawa Y, Wakino S, Saruta T: Differential regulation of elevated renal angiotensin II in chronic renal ischemia. Hypertension. 2002, 40 (1): 34-40. 10.1161/01.HYP.0000022060.13995.ED.CrossRefPubMed
21.
Prieto MC, González-Villalobos RA, Botros FT, Martin VL, Pagán J, Satou R, Lara LS, Feng Y, Fernandes FB, Kobori H, Casarini DE, Navar LG: Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1–7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2011, 300 (3): F749-F755. 10.1152/ajprenal.00383.2009.PubMedCentralCrossRefPubMed
22.
Hartono SP, Knudsen BE, Zubair AS, Nath KA, Textor SJ, Lerman LO, Grande JP: Redox signaling is an early event in the pathogenesis of renovascular hypertension. Int J Mol Sci. 2013, 14 (9): 18640-18656. 10.3390/ijms140918640.PubMedCentralCrossRefPubMed
23.
Weight SC, Bell PR, Nicholson ML: Renal ischaemia-reperfusion injury. Br J Surg. 1996, 83 (2): 162-170. 10.1002/bjs.1800830206.CrossRefPubMed
24.
Meier P, Rossert J, Plouin PF, Burnier M: Atherosclerotic renovascular disease: beyond the renal artery stenosis. Nephrol Dial Transplant. 2007, 22 (4): 1002-1006. 10.1093/ndt/gfl784.CrossRefPubMed
25.
Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, Lee KW: Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol. 2009, 297 (2): 362-370. 10.1152/ajprenal.90609.2008.CrossRef
26.
Cadirci E, Halici Z, Odabasoglu F, Albayrak A, Karakus E, Unal D, Atalay F, Ferah I, Unal B: Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. Clin Exp Immunol. 2011, 166 (3): 374-384. 10.1111/j.1365-2249.2011.04483.x.PubMedCentralCrossRefPubMed
27.
Balarini CM, Leal MA, Gomes IBS, Pereira TMC, Gava AL, Meyrelles SS, Vasquez EC: Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J Transl Med. 2013, 11: 3-10.1186/1479-5876-11-3.PubMedCentralCrossRefPubMed
28.
Rodrigues BP, Campagnaro BP, Balarini CM, Pereira TM, Meyrelles SS, Vasquez EC: Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis. Lipids Health Dis. 2013, 12 (1): 128-10.1186/1476-511X-12-128.PubMedCentralCrossRefPubMed
29.
Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999, 29 (3): 297-310. 10.1080/004982599238687.CrossRefPubMed
30.
Mattson DL: Comparison of arterial blood pressure in different strains of mice. Am J Hypertens. 2001, 14 (5 Pt 1): 405-408.CrossRefPubMed
31.
Folkmann JK, Loft S, Moller P: Oxidatively damaged DNA in aging dyslipidemic ApoE−/− and wild-type mice. Mutagenesis. 2007, 22 (2): 105-110. 10.1093/mutage/gel059.CrossRefPubMed
32.
Folkmann JK, Risom L, Hansen CS, Loft S, Moller P: Oxidatively damaged DNA and inflammation in the liver of dyslipidemic ApoE−/− mice exposed to diesel exhaust particles. Toxicology. 2007, 237: 34-44.CrossRef
33.
Swain U, Subba Rao K: Study of DNA damage via the comet assay and base excision repair activities in rat brain neurons and astrocytes during aging. Mech Ageing Dev. 2011, 132 (8–9): 374-381.CrossRefPubMed
34.
Shaffer RG, Greene S, Arshi A, Supple G, Bantly A, Moore JS, Mohler ER: Flow cytometric measurement of circulating endothelial cells: the effect of age and peripheral arterial disease on baseline levels of mature and progenitor populations. Cytometry ( Part B) Clin Cytom. 2006, 70 (2): 56-62.CrossRef
35.
Tonini CL, Campagnaro BP, Louro LP, Pereira TM, Vasquez EC, Meyrelles SS: Effects of aging and hypercholesterolemia on oxidative stress and DNA damage in bone marrow mononuclear cells in apolipoprotein E-deficient mice. Int J Mol Sci. 2013, 14 (2): 3325-3342. 10.3390/ijms14023325.PubMedCentralCrossRefPubMed
36.
Schachnik NC, Peruhype-Magalhães V, Paula GM, Lucas F, Freitas VM, Martins-Filho OA, Dusse LM: Intracellular nitric oxide assessment in whole blood leukocytes by flow cytometry: optimization and applicability to monitor patients with chronic graft nephropathy. J Immunol Methods. 2009, 343 (2): 103-111. 10.1016/j.jim.2009.01.010.CrossRefPubMed
37.
Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988, 175 (1): 184-191. 10.1016/0014-4827(88)90265-0.CrossRefPubMed
38.
Duez P, Dehon G, Kumps A, Dubois J: Statistics of the comet assay: a key to discriminate between genotoxic effects. Mutagenesis. 2003, 18 (2): 159-166. 10.1093/mutage/18.2.159.CrossRefPubMed
39.
Legrand M, Mik EG, Johannes T, Payen D, Ince C: Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med. 2008, 14 (7–8): 502-516.PubMedCentralPubMed
40.
Uttara B, Singh AV, Zamboni P, Mahajan RT: Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009, 7 (1): 65-74. 10.2174/157015909787602823.PubMedCentralCrossRefPubMed
41.
Vasquez EC, Peotta VA, Gava AL, Pereira TM, Meyrelles SS: Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci. 2012, 19: 22-10.1186/1423-0127-19-22.PubMedCentralCrossRefPubMed
42.
Ghiadoni L, Versari D, Taddei S: Phosphodiesterase 5 inhibition in essential hypertension. Curr Hypertens Rep. 2008, 10 (1): 52-57. 10.1007/s11906-008-0011-4.CrossRefPubMed
43.
Cunha RS, Cabral AM, Vasquez EC: Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am J Hypertens. 1993, 6 (9): 806-809.PubMed
44.
Peotta VA, Vasquez EC, Meyrelles SS: Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38 (3 Pt 2): 555-559.CrossRefPubMed
45.
Milman HA, Arnold SB: Neurologic, psychological, and aggressive disturbances with sildenafil. Ann Pharmacother. 2002, 36 (7–8): 1129-1134.CrossRefPubMed
46.
Fazan R, Huber DA, Silva CA, da Silva VJ D, Salgado MC, Salgado HC: Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol (1985). 2008, 104 (6): 1683-1689. 10.1152/japplphysiol.01142.2007.CrossRef
47.
Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, Kutil B, Kraft R, Klein T, Hocher B: Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens. 2013, 31 (11): 2290-2298. 10.1097/HJH.0b013e3283649b4d. discussion 9CrossRefPubMed
48.
Zhu XY, Urbieta Caceres VH, Favreau FD, Krier JD, Lerman A, Lerman LO: Enhanced endothelial progenitor cell angiogenic potency, present in early experimental renovascular hypertension, deteriorates with disease duration. J Hypertens. 2011, 29 (10): 1972-1979. 10.1097/HJH.0b013e32834ae611.PubMedCentralCrossRefPubMed
49.
Garovic VD, Textor SC: Renovascular hypertension and ischemic nephropathy. Circulation. 2005, 112: 1362-1374. 10.1161/CIRCULATIONAHA.104.492348.CrossRefPubMed
50.
Abdi A, Johns EJ: Importance of the renin-angiotensin system in the generation of kidney failure in renovascular hypertension. J Hypertens. 1996, 14 (9): 1131-1137. 10.1097/00004872-199609000-00014.CrossRefPubMed
51.
Textor SC, Misra S, Oderich GS: Percutaneous revascularization for ischemic nephropathy: the past, present, and future. Kidney Int. 2013, 83 (1): 28-40. 10.1038/ki.2012.363.PubMedCentralCrossRefPubMed
52.
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS: Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation. 2001, 104: 1985-1991. 10.1161/hc4101.096153.CrossRefPubMed
53.
Textor SC, Novick AC, Steinmuller DR, Streem SB: Renal failure limiting antihypertensive therapy as an indication for renal revascularization. Arch Intern Med. 1983, 143: 2208-2211. 10.1001/archinte.1983.00350110202045.CrossRefPubMed
54.
Sattar MA, Yusof AP, Gan EK, Sam TW, Johns EJ: Acute renal failure in 2K2C Goldblatt hypertensive rats during antihypertensive therapy: comparison of an angiotensin AT1 receptor antagonist and clonidine analogues. J Auton Pharmacol. 2000, 20 (5–6): 297-304.CrossRefPubMed
55.
Küçük A, Yucel M, Erkasap N, Tosun M, Koken T, Ozkurt M, Erkasap S: The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats. Mol Biol Rep. 2012, 39 (10): 9775-9782. 10.1007/s11033-012-1843-1.CrossRefPubMed
56.
Wan X, Chen X, Liu L, Zhao Y, Huang WJ, Zhang Q, Miao GG, Chen W, Xie HG, Cao CC: Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFκB signaling pathway in rats. PLoS One. 2013, 8 (3): e59794-10.1371/journal.pone.0059794.PubMedCentralCrossRefPubMed
57.
Porto ML, Lima LC, Pereira TM, Nogueira BV, Tonini CL, Campagnaro BP, Meyrelles SS, Vasquez EC: Mononuclear cell therapy attenuates atherosclerosis in apoE KO mice. Lipids Health Dis. 2011, 10: 155-10.1186/1476-511X-10-155.PubMedCentralCrossRefPubMed
58.
59.
Roe ND, Ren J: Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascul Pharmacol. 2012, 57 (5–6): 168-172.CrossRefPubMed
60.
Guimarães DA, Rizzi E, Ceron CS, Pinheiro LC, Gerlach RF, Tanus-Santos JE: Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension. Redox Biol. 2013, 1 (1): 578-585. 10.1016/j.redox.2013.11.004.PubMedCentralCrossRefPubMed
61.
Whiting C, Castillo A, Haque MZ, Majid DS: Protective role of the endothelial isoform of nitric oxide synthase in ANG II-induced inflammatory responses in the kidney. Am J Physiol Renal Physiol. 2013, 305 (7): F1021-F1041.CrossRef
62.
Ebrahimi F, Shafaroodi H, Asadi S, Nezami BG, Ghasemi M, Rahimpour S, Hashemi M, Doostar Y, Dehpour AR: Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. Can J Physiol Pharmacol. 2009, 87 (7): 556-564. 10.1139/Y09-036.CrossRefPubMed
63.
Hemnes AR, Zaiman A, Champion HC: PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol. 2008, 294 (1): L24-L33.CrossRefPubMed
64.
Koupparis AJ, Jeremy JY, Muzaffar S, Persad R, Shukla N: Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int. 2005, 96 (3): 423-427. 10.1111/j.1464-410X.2005.05643.x.CrossRefPubMed
65.
Elrod JW, Greer JJ, Lefer DJ: Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol. 2007, 292 (1): H342-H347.CrossRefPubMed
66.
Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ: Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol. 2009, 29 (3): 274-282. 10.1159/000158635.CrossRefPubMed
67.
Kim KH, Kim YJ, Ohn JH, Yang J, Lee SE, Lee SW, Kim HK, Seo JW, Sohn DW: Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012, 125 (11): 1390-1401. 10.1161/CIRCULATIONAHA.111.065300.CrossRefPubMed
68.
Modrall JG, Rosero EB, Timaran CH, Anthony T, Chung J, Valentine RJ, Trimmer C: Assessing outcomes to determine whether symptoms related to hypertension justify renal artery stenting. J Vasc Surg. 2012, 55 (2): 413-419. 10.1016/j.jvs.2011.08.056.CrossRefPubMed
69.
McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985, 312 (3): 159-163. 10.1056/NEJM198501173120305.CrossRefPubMed
70.
Zheng J, Devalaraja-Narashimha K, Singaravelu K, Padanilam BJ: Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am J Physiol Renal Physiol. 2005, 288 (2): F387-F398.CrossRefPubMed
71.
Ückert S, Kuczyk MA, Oelke M: Phosphodiesterase inhibition in clinical urology. Expert Rev Clin Pharmacol. 2013, 6 (3): 323-332. 10.1586/ecp.13.16.CrossRefPubMed
72.
Aicher A, Zeiher AM, Dimmeler S: Mobilizing endothelial progenitor cells. Hypertension. 2005, 45: 321-325. 10.1161/01.HYP.0000154789.28695.ea.CrossRefPubMed
73.
Rookmaaker MB, Verhaar MC, de Boer HC, Goldschmeding R, Joles JA, Koomans HA, Grone HJ, Rabelink TJ: Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo. Am J Physiol Renal Physiol. 2007, 293: F624-F630. 10.1152/ajprenal.00398.2006.CrossRefPubMed
74.
Lavi R, Zhu XY, Chade AR, Lin J, Lerman A, Lerman LO: Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2010, 30: 976-983. 10.1161/ATVBAHA.109.201475.PubMedCentralCrossRefPubMed
75.
Wu VC, Young GH, Huang PH, Lo SC, Wang KC, Sun CY, Liang CJ, Huang TM, Chen JH, Chang FC, Chen YL, Kuo YS, Chen JB, Chen JW, Chen YM, Ko WJ, Wu KD, NSARF group: In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin. Angiogenesis. 2013, 16 (3): 609-624. 10.1007/s10456-013-9339-8.CrossRefPubMed
76.
Aleksinskaya MA, van Faassen EE, Nelissen J, Janssen BJ, De Mey JG, Hanemaaijer R, Rabelink T, van Zonneveld AJ: Identification of free nitric oxide radicals in rat bone marrow: implications for progenitor cell mobilization in hypertension. PLoS One. 2013, 8 (3): e57761-10.1371/journal.pone.0057761.PubMedCentralCrossRefPubMed
77.
Dussault S, Maingrette F, Ménard C, Michaud S-E, Haddad P, Groleau J, Turgeon J, Perez G, Rivard A: Sildenafil increases endothelial progenitor cell function and improves ischemia-induced neovascularization in hypercholesterolemic apolipoprotein E deficient mice. Hypertension. 2009, 54: 1043-1049. 10.1161/HYPERTENSIONAHA.109.139451.CrossRefPubMed
78.
Lima LCF, Porto ML, Campagnaro BP, Tonini CL, Nogueira BV, Pereira TM, Vasquez EC, Meyrelles SS: Mononuclear cell therapy reverts cuff-induced thrombosis in apolipoprotein E-deficient mice. Lipids Health Dis. 2012, 11: 96-10.1186/1476-511X-11-96.PubMedCentralCrossRefPubMed
Metadata
Title
Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension
Authors
Ananda T Dias
Bianca P Rodrigues
Marcella L Porto
Agata L Gava
Camille M Balarini
Flavia P S Freitas
Zaira Palomino
Dulce E Casarini
Bianca P Campagnaro
Thiago M C Pereira
Silvana S Meyrelles
Elisardo C Vasquez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-35

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue

Research

let-7b/g silencing activates AKT signaling to promote gastric carcinogenesis

Research

Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts

Research

Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?

Research

On the inflammatory response in metal-on-metal implants

Research

PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study

Research

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits